PTAB Upholds Seer's Nano‑Particle Protein Enrichment Patent, Securing 23 Claims

Why It Matters

The PTAB’s affirmation safeguards a foundational technology that enables deep, unbiased proteomic analysis—a capability increasingly critical for drug discovery, precision medicine and biomarker validation. By confirming the enforceability of Seer’s nanoparticle enrichment methods, the ruling reduces legal risk for customers and investors, encouraging broader adoption of the Proteograph platform. Beyond Seer, the decision sets a precedent for how courts may evaluate nanotech‑based biotech patents that blend materials science with analytical chemistry. It highlights the growing importance of intellectual property protection in a sector where incremental innovations in particle engineering can translate into substantial commercial advantage.

Key Takeaways

• PTAB upheld 23 of 29 claims in Seer's U.S. Patent No. 11,435,360 B2 on March 23, 2026.
• The challenged patent underpins Seer's Proteograph platform, which uses engineered nano‑ and micro‑particles for protein enrichment.
• Challengers PreOmics GmbH and Biognosys AG, subsidiaries of Bruker, contested 11 claims but failed to overturn the core IP.
• Seer's IP portfolio now exceeds 240 issued patents and pending applications, including 80 issued patents covering its nanoparticle technology.
• The ruling removes legal uncertainty for Seer's biotech customers and may accelerate licensing and partnership activity.

Pulse Analysis

Seer’s victory at the PTAB is more than a defensive win; it reinforces the strategic value of nanomaterial‑driven proteomics in a market hungry for deeper molecular insight. Historically, proteomics has been limited by dynamic range and throughput, forcing researchers to rely on targeted assays or labor‑intensive workflows. Seer’s Proteograph platform, built on proprietary particle chemistries, sidesteps these constraints by creating a protein corona that preferentially captures low‑abundance species, delivering data that rivals traditional mass‑spectrometry depth with higher reproducibility.

The decision also sends a clear message to investors: robust, defensible patents can protect high‑margin, technology‑intensive business models in biotech. Seer’s stock, already buoyed by its Nasdaq listing and a growing customer base, may see renewed confidence as the risk of an IP injunction recedes. Competitors that have been eyeing Seer’s approach—such as emerging startups developing alternative nanoparticle coatings—will now need to either license the technology or invest heavily in distinct chemistries, potentially slowing their time‑to‑market.

Looking forward, the real test will be how Seer leverages this cleared IP to expand its platform beyond research use. If the company can translate its deep proteomic data into clinically actionable insights, it could unlock new revenue streams in diagnostics and companion‑therapy development. The PTAB ruling, therefore, is a catalyst that could accelerate both commercial partnerships and the broader adoption of nanotech‑enabled proteomics across the life‑science ecosystem.